Press Releases

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma publishes prospectus in connection with rights issue

Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019

Promore Pharma engages ABG Sundal Collier as liquidity provider

Nomination Committee Appointed for the Annual General Meeting 2020 in Promore Pharma

Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)

Promore Pharma Rights issue – correction of date

Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early

Promore Pharma AB (publ) Interim report January – June 2019

Promore Pharma is granted a patent for LL-37 in Japan

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019

Promore Pharma has recruited half of the patients in HEAL LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019

Promore Pharma AB (publ) Interim report January – March 2019

Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2019

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma AB (publ) Year-end report 2018

Invitation to Presentation of Promore Pharma’s Year-end report for 2018

Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study

Subscription price for Promore Pharma’s warrants TO1 determined